Sarepta Therapeutics, Inc. (0L35.L) LSE

20.24

-0.5307(-2.56%)

Updated at April 23 04:43PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Douglas S. Ingram	Chief Executive Officer & Director	1.98M	1963
Joseph Bratica	Controller & Vice President	438,513	1964
Louise R. Rodino-Klapac	President of Research & Development and Technical Operations	1.12M	1978
Ian Michael Estepan	President & COO	1.14M	1976
Diane L. Berry	Executive VP and Chief of Global Policy & Advocacy Officer	0	N/A
Alison Nasisi	Executive VP & Chief People Officer	0	N/A
Cristin L. Rothfuss	Executive VP, Chief General Counsel & Corporate Secretary	0	N/A
Patrick Moss	Executive VP & Chief Commercial Officer	0	N/A
Rachael Potter	Chief Scientific Officer	0	N/A
Ryan H. Wong	Executive VP & CFO	0	N/A
Tamara Thornton	Director of Finance, Treasury & Investor Relations	0	N/A

Name

Title

Pay

Year Born

Douglas S. Ingram

Chief Executive Officer & Director

1.98M

1963

Joseph Bratica

Controller & Vice President

438,513

1964

Louise R. Rodino-Klapac

President of Research & Development and Technical Operations

1.12M

1978

Ian Michael Estepan

President & COO

1.14M

1976

Diane L. Berry

Executive VP and Chief of Global Policy & Advocacy Officer

N/A

Alison Nasisi

Executive VP & Chief People Officer

N/A

Cristin L. Rothfuss

Executive VP, Chief General Counsel & Corporate Secretary

N/A

Patrick Moss

Executive VP & Chief Commercial Officer

N/A

Rachael Potter

Chief Scientific Officer

N/A

Ryan H. Wong

Executive VP & CFO

N/A

Tamara Thornton

Director of Finance, Treasury & Investor Relations

N/A

Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.